share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Claiborne Cary J

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股變動聲明
美股SEC公告 ·  03/28 06:10
牛牛AI助理已提取核心訊息
Claiborne Cary J, the Chief Executive Officer of Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock on March 25, 2024. Unfortunately, the announcement does not provide details on the number of shares transacted, the nature of the shares, the transaction price, or the total value of the transaction. Additionally, the number of shares held by Claiborne Cary J after the transaction is not disclosed. Investors are advised to seek further information to fully understand the impact of this event on their investment decisions.
Claiborne Cary J, the Chief Executive Officer of Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock on March 25, 2024. Unfortunately, the announcement does not provide details on the number of shares transacted, the nature of the shares, the transaction price, or the total value of the transaction. Additionally, the number of shares held by Claiborne Cary J after the transaction is not disclosed. Investors are advised to seek further information to fully understand the impact of this event on their investment decisions.
阿迪爾製藥公司（ADIL）首席執行官克萊伯恩·卡里·J於2024年3月25日參與了一項涉及該公司股票的交易。不幸的是，該公告沒有提供有關交易的股票數量、股票性質、交易價格或交易總價值的詳細信息。此外，Claiborne Cary J在交易後持有的股票數量沒有披露。建議投資者尋求更多信息，以充分了解這一事件對其投資決策的影響。
阿迪爾製藥公司（ADIL）首席執行官克萊伯恩·卡里·J於2024年3月25日參與了一項涉及該公司股票的交易。不幸的是，該公告沒有提供有關交易的股票數量、股票性質、交易價格或交易總價值的詳細信息。此外，Claiborne Cary J在交易後持有的股票數量沒有披露。建議投資者尋求更多信息，以充分了解這一事件對其投資決策的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。